Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Sunday's Bonus Story 3 "Forever Stocks" to Hold When the Market Won't Sit StillSubmitted by Chris Markoch. Originally Published: 1/19/2026. 
In Brief - Chevron provides long-term income potential through disciplined buybacks, a growing dividend, and exposure to global energy markets.
- Colgate-Palmolive delivers consistency with a diversified brand portfolio and more than six decades of annual dividend increases.
- Merck combines near-term cash flow from Keytruda with a late-stage oncology pipeline aimed at sustaining future growth.
With so much volatility in the market, it's a good time for investors to consider stocks they can hold for the long haul. These compounders don't need to make up a large portion of your portfolio, but they're useful for investors who prefer to step away from their screens. Owning "forever stocks" is about more than chasing the next hot trade. It means building a portfolio around companies with durable competitive advantages, resilient cash flows, and shareholder-friendly capital allocation. Those businesses can weather economic cycles, adapt to industry shifts, and continue rewarding investors through dividends and long-term appreciation. There are 90 paper gold claims for every real ounce in COMEX vaults. Ninety promises, one ounce of metal. It's like musical chairs with 90 players and one chair. COMEX gold inventory dropped 25 percent last year alone as gold flows East to Shanghai, Mumbai, and Moscow. On March 31st, contract holders can demand delivery. When similar situations arose in the past, markets closed and rules changed. Paper holders got crushed while mining stock holders made fortunes. One stock sits at the center of this crisis. Get the full story on this opportunity now. Large-cap leaders with global footprints often fit this profile. They benefit from scale, strong brands, and balance sheets that allow them to invest through downturns while returning capital to shareholders. While even the best companies can experience periods of underperformance, history shows patience is often rewarded when the underlying business remains strong. Chevron: Energy Income With Long-Term Staying Power Chevron Corp. (NYSE: CVX) is a large-cap integrated oil giant with operations in the Permian Basin and several deep-water projects; it also has investments in renewable energy. CVX's stock price is sensitive to oil-price fluctuations. That's a key reason the stock produced a total return of just 5.1% over the past three years. Despite producers pumping at or near record levels, crude remains in the high $50s to low $60s, putting pressure on earnings. Still, over the last 10 years CVX stock has delivered a total return of more than 200%. The company has a history of share buybacks and a growing, reliable dividend, which currently yields 4.12%. Perhaps more important is the annualized payout of $6.84 per share and Chevron's status as a dividend aristocrat, with 38 consecutive years of dividend increases. Colgate-Palmolive: A Dividend King Built for Consistency Colgate-Palmolive Co. (NYSE: CL) is a leading name among consumer staples stocks. The company has a deep portfolio of brands that reach consumers around the world. The bullish case for CL traces back to Peter Lynch's advice to "own what you know"—its products have stable, long-term demand. Recent investors may need a strong stomach: this "forever" stock has returned about 15% over the past five years, including the company's dividend, which yields 2.47%. Over longer time spans, CL has been a reliable compounder of wealth thanks to its status as a dividend king. The company has increased its dividend for 63 consecutive years. At roughly 22x earnings, the stock appears reasonably valued relative to its history and the broader market. Merck: Pipeline-Driven Growth Beyond Keytruda Merck & Co. (NYSE: MRK) took investors on a roller-coaster in 2025, falling to about $72 — roughly 45% below its June 2024 high. Like the other names here, MRK has been a tough hold recently, delivering a total return of just over 10% in the last three years. Merck depends on its blockbuster drug Keytruda for nearly half of its revenue. Keytruda won't face the patent cliff until 2028, but institutional investors are forward-looking and want to know how Merck plans to replace that revenue. The challenge is similar to the one AbbVie Inc. (NYSE: ABBV) faced with Humira; AbbVie ultimately replaced much of that lost revenue, and Merck needs to demonstrate a comparable outcome. Confidence rests on Merck's pipeline. The company is pursuing additional indications for Keytruda and has 16 oncology drugs in late-stage trials. Approval of even one or two of those candidates in the next couple of years could materially offset the Keytruda shortfall.
| 
Post a Comment
Post a Comment